Author:
Kinuya Seigo,Yoshinaga Keiichiro,Higuchi Tetsuya,Jinguji Megumi,Kurihara Hiroaki,Kawamoto Hiroshi
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference55 articles.
1. Nakajo M, Yoshinaga K, Oriuchi N, Kinuya S, Yokoyama K, Yamaguchi T, et al. Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors. Kaku igaku Jpn J Nucl Med. 2008;45(1):1–40.
2. Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Effects and safety of I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014.
3. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002;94(7):2081–9.
4. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011;56(2):191–201.
5. Shapiro B. Summary, conclusions, and future directions of [131I] metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med. 1991;35(4):357–63.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献